REQUEST A DEMO
Total
USD $0.00
Search more companies

Medigen Biotechnology Corporation (Taiwan, China)

Main Activities: Research and Development in the Physical, Engineering, and Life Sciences
Full name: Medigen Biotechnology Corporation Profile Updated: May 24, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Chinese Download a sample report

The company was established in 1999, focusing on providing supports and technologies developed exclusively by the Australian firm Progen. The company primarily conducts tests on medicines that aim for terminal cancer treatments. It has then developed its own cell biology labs and molecular biology labs, focusing in particular on the oncological and immunological experiments.

Headquarters
14F.,Bldg.F,No.3,Yuancyu St, Nangang District
Taipei City; Taipei City;

Contact Details: Purchase the Medigen Biotechnology Corporation report to view the information.

Website: http://www.medigen.com.tw

Basic Information
Total Employees:
Purchase the Medigen Biotechnology Corporation report to view the information.
Outstanding Shares:
Purchase the Medigen Biotechnology Corporation report to view the information.
Financial Auditors:
Purchase the Medigen Biotechnology Corporation report to view the information.
Incorporation Date:
December 31, 1999
Key Executives
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
Assistant Vice President
Ownership Details
Purchase this report to view the information.
10.11%
Purchase this report to view the information.
3.14%
Purchase this report to view the information.
1.74%
Purchase this report to view the information.
1.29%
Purchase this report to view the information.
Subsidiaries
基亞生物科技(北京)有限公司 (China)
100%
基亞生物科技(廈門)有限公司 (China)
100%
迎鑫投資(股)公司
100%
Company Performance
Financial values in the chart are available after Medigen Biotechnology Corporation report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency TWD. Absolute financial data is included in the purchased report.
Net sales revenue
63.71%
Total operating revenue
58.4%
Operating profit (EBIT)
80.88%
EBITDA
79.79%
Net Profit (Loss) for the Period
84.99%
Total assets
-26.66%
Total equity
-12.28%
Operating Profit Margin (ROS)
141.65%
Net Profit Margin
148.13%
Return on Equity (ROE)
8.62%
Debt to Equity Ratio
5.46%
Quick Ratio
1.08%
Cash Ratio
1.25%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?